INTRODUCTION {#s1}
============

Esophageal cancer is the 8^th^ most prevalent cancer around the globe \[[@R1]\]. Esophageal squamous cell carcinoma (ESCC) and adenocarcinoma are two major types of esophageal cancer. The global age-standardized incidence rate of ESCC is 1.4-13.6 per 100,000 people \[[@R1]\]. Patients with early, localized esophageal cancer can benefit from esophagectomy \[[@R2]\]. Patients with locally advanced, unresectable esophageal cancer are treated with various chemotherapy regimens or concurrent chemoradiotherapy (CCRT) to prolong their survival and/or to improve their quality of life \[[@R3]--[@R6]\]. A randomized trial have demonstrated the superiority of CCRT in comparison with radiotherapy alone \[[@R7]\]. Besides, CCRT has been shown an effective therapeutic modality for neoadjuvant treatment before surgical resections \[[@R6], [@R8], [@R9]\]. The most frequently used chemotherapy regimens are a combination of 5-fluorouracil and cisplatin \[[@R10]\]. Clinically, a wide diversity of response rates of CCRT has been observed (15 to 45%) \[[@R10]\]. Unfortunately, \~50% of the esophageal cancer patients, when first diagnosed, were already at a far advanced stage with cancer metastasis \[[@R11]\]. Patients of this stage have a mean survival time less than 8.1 months \[[@R10]\]. The standard treatments have not been established for metastatic esophageal cancer \[[@R2]\]. It remained elusive whether the chemoradiotherapeutic response can be translated to survival benefits in advanced esophageal cancer patients \[[@R2], [@R6]\].

CCRT has a high-toxicity profile which restricts its clinical use. The capability to predict therapeutic responses are thus urgently needed for clinicians to select suitable patient groups for aggressive treatments \[[@R12], [@R13]\]. Many potential therapeutic response predictors have been reported for early or locally advanced esophageal cancer in the literature \[[@R14]--[@R22]\]. However, to date, no genetic response predictor has ever been identified for chemoradiotherapy in ESCC patients with cancer metastasis. Recently, the genotypes of the *GALNT14*-rs9679162 single nucleotide polymorphism (SNP) has been shown to be an effective predictor for systemic chemotherapy response in advanced hepatocellular carcinoma (HCC), based on a genome-wide exploration of 500,000 SNPs in human white blood cells \[[@R23]\], and subsequent prospective \[[@R24]\] and retrospective validations \[[@R25], [@R26]\]. This genotype was further demonstrated to be an effective outcome predictor of transcatheter arterial chemoembolization treatment (TACE) for intermediate-stage HCC patients \[[@R27]\]. In all these studies, the *GALNT14* rs9679162 "T" allele was associated to favorable outcomes of patients, while the "G" allele was associated to poor outcomes. The systemic combination chemotherapy regimens used for the previous studies were 5- fluorouracil, cisplatin and mitoxantrone, of which two were commonly used for advanced ESCC. Furthermore, the GALNT14 protein has been shown to be able to enhance the extrinsic apoptotic signaling of cancer cells \[[@R27], [@R28]\]. It would be interesting to know if *GALNT14* genotype could be a predictor of chemoradiotherapeutic response in patients with advanced ESCC.

Therefore, the main goals of this study were (i) to examine whether the chemoradiotherapeutic response was associated with survival benefits in advanced ESCC patients; and (ii) whether the *GALNT14* genotypes were associated with the chemoradiotherapeutic response.

RESULTS {#s2}
=======

Baseline characteristics of the patients {#s2_1}
----------------------------------------

A total of 108 patients were included, and their basic clinical data were listed in Table [1](#T1){ref-type="table"}. Most patients were male (96.3%). Most of them had an ECOG performance status score of 1 or 0 (83.3%). Among all patients, 34.3% had tumors across two regions. The percentages of patients with tumors located only in the upper, middle, or lower esophagus were 19.4%, 25.0% and 21.3%, respectively. The most common histological grading was moderately differentiated (67.9%), followed by poorly differentiated (25.5%). Tumor length was 7.6 ± 3.7 cm. With regard to tumor stage, 45.4% of the patients had T3 and 46.3% had T4 diseases. When considering the metastasis stage, 38%, 12%, and 50%, respectively, had regional LNs, distant LNs, and organ metastasis.

###### Baseline clinical data of the 108 advanced esophageal cancer patients included

  Parameters                              
  --------------------------------------- -------------------------------------
  Age, years, mean ± SD                   52.6 ± 9.4
  Gender, Male (%)                        104 (96.3)
  Location of cancer                      
   Upper esophagus (%)                    21 (19.4)
   Middle esophagus (%)                   27 (25.0)
   Lower esophagus (%)                    23 (21.3)
   Cross two regions (%)                  37 (34.3)
  Histology grading                       
   Well differentiated (%)                4 (3.7)
   Moderate differentiated (%)            72 (67.9)
   Poorly differentiated (%)              27 (25.5)
   Not graded (%)^a^                      3 (2.8)
  Tumor stage                             
   T1/ T2/ T3/ T4 (%)                     1/ 8/ 49/ 50 (0.9/ 7.4/ 45.4/ 46.3)
  Metastasis stage                        
   Regional N/ Distant N/ O (%)^b^        41/ 13/ 54 (38.0/ 12.0/ 50.0)
  ECOG stage                              
   Stage 0/ 1                             16/ 74 (14.8/ 68.5)
   \> 1                                   18 (16.7)
  Tumor length, cm, mean ± SD             7.6 ± 3.7
  Biochemistry and hemogram               
   Albumin, g/dL, mean ± SD               3.7 ± 0.6
   Alanine transaminase, U/L, mean ± SD   21.4 ± 15.6
   Creatinine, mg/dL, mean ± SD           0.7 ± 0.3
   Bilirubin, mg/dL, mean ± SD            0.6 ± 0.5
   Leukocytes, × 10^9^/L, mean ± SD       9.3 ± 4.2
   Neutrophil percentages, %, mean ± SD   70.4 ± 11.6
   Hemoglobin, g/dL, mean ± SD            12.0 ± 2.2
  *GALNT14* genotype                      
   TT                                     28 (25.9)
   GG                                     29 (26.9)
   TG                                     51 (47.2)

^a^Histology was accessed at other hospitals.

^b^N, lymph node; O, organ.

In this cohort, the numbers of patients of the *GALNT14* rs9679162 "TT", "TG" and "GG" genotypes were 28 (25.9%), 51 (47.2%) and 29 (26.9%), respectively. This genotype distribution did not deviate significantly from those of the HapMap Chinese Han Beijing (CHB) and Metropolitan Denver (CHD) ethnic reference cohorts (Cochran-Armitage Trend test, P = 0.422 and 0.575, respectively).

Complete/partial responses to CCRT was positively associated with overall survival, independent of tumor locations, metastasis stages and tumor lengths {#s2_2}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Therapeutic responses of CCRT were analyzed for their association with overall survival, alongside other clinical variables. Based on the RECIST definition \[[@R29]\], patients were classified into two groups: the responder group which included patients with complete and partial responses, respectively; and the non-responder group which included patients with stable disease and progressive disease, respectively. In the univariate analysis, tumor location, metastasis stage, ECOG status, tumor length, pre-treatment serum levels of albumin and alanine transaminase, level of hemoglobin, and therapeutic response (including complete and partial responses) to CCRT were associated significantly with the overall survival (Table [2](#T2){ref-type="table"}).

###### Cox proportional hazard analysis for overall survival in relation to clinical parameters

  Clinical parameters                        Univariate analysis   Multivariate analysis                                           
  ------------------------------------------ --------------------- ----------------------- -------------- ------- ---------------- --------------
  Age, per year increase                     0.991                 0.973 -- 1.010          0.359                                   
  Gender, Male = 1                           0.469                 0.171 -- 1.286          0.141                                   
  Location of tumor                                                                                                                
   Upper = 1                                 0.712                 0.440 -- 1.151          0.165                                   
   Middle = 1                                1.076                 0.691 -- 1.675          0.746                                   
   Lower = 1                                 1.759                 1.090 -- 2.839          **0.021**      2.462   1.416 -- 4.281   **0.001**
  Histology, Poorly differentiated = 1       1.198                 0.778 -- 1.846          0.412                                   
  Tumor stage, per stage increase            1.235                 0.912 -- 1.673          0.173                                   
  Metastasis stages, per stage increase^a^   1.434                 1.159 -- 1.775          **0.001**      1.659   1.253 -- 2.196   **\< 0.001**
  ECOG Stage, greater than one = 1           2.062                 1.230 -- 3.458          **0.006**      0.661   0.357 -- 1.225   0.188
  Tumor length, per mm increase              1.009                 1.003 -- 1.014          **0.002**      1.007   1.000 -- 1.013   **0.045**
  Albumin, per g/dL increase                 0.580                 0.388 -- 0.868          **0.008**      0.832   0.529 -- 1.307   0.424
  Alanine transaminase, per U/L increase     1.020                 1.008 -- 1.033          **0.001**      1.008   0.995 -- 1.022   0.213
  Creatinine, per mg/dL increase             1.013                 0.456 -- 2.251          0.974                                   
  Bilirubin, per mg/dL increase              1.142                 0.771 -- 1.691          0.509                                   
  Leukocytes, per × 10^9^/L increase         1.050                 0.999 -- 1.103          0.054                                   
  Neutrophil percentage, per % increase      2.676                 0.505 -- 14.187         0.247                                   
  Hemoglobin, per g/dL increase              0.890                 0.814 -- 0.973          **0.010**      0.947   0.851 -- 1.053   0.311
  Complete/partial response = 1              0.474                 0.320 -- 0.702          **\< 0.001**   0.360   0.227 -- 0.572   **\< 0.001**

^a^Stage 1, 2, and 3 were defined as regional lymph nodes involvement only, distant lymph nodes involvement, and distant organ metastasis.

In the multivariate analysis, tumor location, metastasis stage, tumor length, and complete/partial response to CCRT remained significantly associated to overall survival. Patients with tumor in lower esophagus demonstrated poorer overall survival than in other locations (adjusted hazard ratio = 2.462, P = 0.001). Significant higher hazards were associated with an increment of metastasis stages (adjusted hazard ratio = 1.659, P \< 0.001), where the stage 1, 2, and 3 indicated respectively regional lymph nodes involvement only, distant lymph nodes involvement, and distant organ metastasis. A longer length of the largest tumor was also associated significantly with poorer overall survival (adjusted hazard ratio = 1.007, P = 0.045).

The adjusted hazard ratio of complete/partial responses to overall survival was 0.360 (95% confidence interval = 0.227 -- 0.572). As such, the presence of complete/partial responses to CCRT was critical for the patients to achieve a longer overall survival, independent of tumor location, metastasis stages, tumor size and other characteristics.

GALNT14 genotype "GG" was significantly associated with poorer therapeutic responses of CCRT {#s2_3}
--------------------------------------------------------------------------------------------

*GALNT14* rs9679162 genotype distributions were significantly associated with therapeutic responses by the Cochran-Armitage Trend test (P = 0.047). We also analyzed dichotomized patient strata using genotypes: (1) "GG" versus "TT+TG"; and (2) "TT" versus "GG+TG", to accommodate both the dominant and receive modes of inheritance. In (1), a significant association was found (P = 0.014, Table [3](#T3){ref-type="table"}). 24.1% of the GG-typed patients had complete or partial response, in contrast to 50.6% of the TT/TG-typed patients. In (2), no significant difference was found (P = 0.422). Therefore, we used the dichotomized strata of patients with genotype "GG" and "TT+TG" respectively for all the following analysis.

###### The association between the therapeutic responses of CCRT and *GALNT14* genotypes

  *GALNT14* genotype   Therapeutic responses   P                         
  -------------------- ----------------------- ------------ ------------ -----------
  "GG"                 29                      22 (75.9%)   7 (24.1%)    
  "TT+TG"              79                      39 (49.4%)   40 (50.6%)   **0.014**
  "TT"                 28                      14 (50.0%)   14 (50.0%)   
  "GG+TG"              80                      47 (58.8%)   33 (41.3%)   0.422

SD, stable disease; PD, progressive disease.

CR, complete response; PR, partial response.

GALNT14 "GG" was associated with longer time-to-complete/partial response, independent of gender and leukocyte counts {#s2_4}
---------------------------------------------------------------------------------------------------------------------

We further conducted a univariate/multivariate analysis on the time-to-responses to CCRT using the Cox proportional hazards model. Since the clinical events analyzed here (complete or partial responses) were favorable events rather than hazardous events, a hazard ratio larger than 1 actually indicated favorable predictors (shorter time-to-responses). Univariate analysis revealed that pre-treatment leukocyte count, gender and the *GALNT14* genotype were associated to time to complete/partial responses (Table [4](#T4){ref-type="table"}). In the multivariate analysis of the three variables, only the *GALNT14* genotypes and the pre-treatment leukocyte count remained statistically significant. Patients with the *GALNT14* genotype "GG" showed longer time to complete/partial responses than those with the "TT" or "TG" genotype (adjusted hazard ratio = 0.385, P = 0.022). This was also demonstrated in the Kaplan-Meier time-to-response curves (Figure [1](#F1){ref-type="fig"}) where the genotype "GG" was associated with poor outcomes (log Rank P = 0.015). Also, patients with higher pre-treatment leukocyte counts showed shorter time to complete/partial responses (adjusted hazard ratio = 1.087, P = 0.014). The significant result in the multivariate analysis showed that *GALNT14* genotypes and the pre-treatment leukocyte count were independently associated with the time to complete/partial response of CCRT.

###### Cox proportional hazard analysis for time-to-CCRT responses (including complete and partial response) in relation to clinical parameters

  Clinical parameters                      Univariate analysis   Multivariate analysis                                        
  ---------------------------------------- --------------------- ----------------------- ----------- ------- ---------------- -----------
  Age, per year increase                   1.008                 0.980 -- 1.036          0.595                                
  Gender, Male vs. Female                  0.203                 0.047 -- 0.886          **0.034**   0.242   0.055 -- 1.064   0.060
  Location of tumor                                                                                                           
   Upper vs. other                         0.939                 0.453 -- 1.950          0.867                                
   Middle vs. other                        1.130                 0.604 -- 2.116          0.703                                
   Lower vs. other                         1.539                 0.726 -- 3.262          0.261                                
  Histology, Poorly differentiated = 1     0.927                 0.479 -- 1.794          0.822                                
  Tumor stage, per stage increase          1.222                 0.788 -- 1.896          0.371                                
  Metastasis stage, per stage increase     1.080                 0.793 -- 1.472          0.623                                
  ECOG Stage, greater than one = 1         0.476                 0.166 -- 1.367          0.168                                
  Tumor length, per cm increase            1.007                 1.000 -- 1.015          0.065                                
  Albumin, per g/dL increase               1.605                 0.895 -- 2.877          0.112                                
  Alanine transaminase, per U/L increase   1.004                 0.983 -- 1.025          0.721                                
  Creatinine, per mg/dL increase           0.716                 0.264 -- 1.943          0.511                                
  Bilirubin, per mg/dL increase            0.902                 0.424 -- 1.920          0.790                                
  Leukocytes, per × 10^9^/L increase       1.084                 1.016 -- 1.156          **0.014**   1.087   1.017 -- 1.161   **0.014**
  Neutrophil percentage, per % increase    5.022                 0.439 -- 57.443         0.194                                
  Hemoglobin, per g/dL increase            1.109                 0.951 -- 1.292          0.186                                
  *GALNT14* genotype, "TT" vs. "TG+GG"     1.423                 0.759 -- 2.671          0.272                                
  *GALNT14* genotype, "GG" vs. "TT+TG"     0.381                 0.170 -- 0.855          **0.019**   0.385   0.171 -- 0.869   **0.022**

![Kaplan-Meier curve of the time to response (including complete and partial response) of patients stratified by the *GALNT14* "GG" and "non-GG" genotypes\
Patients with the "GG" genotype showed longer time to response (log-Rank P = 0.015) than those with the "non-GG" genotype.](oncotarget-08-29151-g001){#F1}

Distribution of *GALNT14* rs9679162 genotypes with respect to gender, location of tumor and metastasis stages were shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. To further evaluate any potential confounding relationships between *GALNT14* genotypes and all the other baseline variables, a logistic regression analysis was performed. The result showed that the *GALNT14* genotype ("GG" versus "TT+TG") did not associate significantly with any other variable, including gender and pretreatment leucocyte counts ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

In our hospital, CCRT was frequently given as a palliative treatment in ESCC patients with cancer metastasis to relieve esophageal obstruction. The present study demonstrated that \~43.52% of such patients can achieve complete/partial response by CCRT. The complete/partial response was positively associated with better overall survival (Adjusted P \< 0.001), independent of tumor location, length and metastasis stage. Therefore, a complete/partial response to CCRT should be rigorously pursued in the initial stage of treatment, as they can be translated into longer overall survival.

The next question was that whether the CCRT responses can be predicted effectively before treatment. The current study demonstrated that the *GALNT14* genotyping can serve as a tool for clinicians to decide in the commencing stage of CCRT whether CCRT alone is sufficient to achieve a complete or partial response. The *GALNT14* genotype, "TT+TG", was associated with favorable treatment responses to CCRT in advanced ESCC patients, while the genotype "GG" was associated with unfavorable outcomes (Table [3](#T3){ref-type="table"}). This result was in agreement with the chemotherapy or chemoembolization treatment of unresectable hepatocellular carcinoma, where the "T" allele consistently indicated favorable outcomes \[[@R23], [@R24], [@R27]\]. The percentages of "TT+TG" patients in this study cohort, as well as in the HapMap Chinese Han Beijing (CHB) and Metropolitan Denver (CHD) ethnic reference cohorts, were 73.2%, 76.5% and 76.2% respectively. This implied that a majority of ESCC patients with cancer metastasis were potential responders to CCRT, while those with the "GG" genotype may need other novel treatments, for example, the addition of docetaxel to CCRT \[[@R3], [@R10], [@R30]\].

The *GALNT14* gene encodes a glycosyltransferase GalNac-T14 which is involved in protein post-translational O-linked glycosylation. It catalyzes the initiation of glycosylation, by conjugating the sugar molecule N-acetyl-D-galactosamine (GalNac) into the Serine or Threonine residues of the protein. On top of the GalNac moiety, further glycosylation can take place. In a genome-wide investigation of consanguineous families, *GALNT14* was identified to bear damaging Mendelian mutations which caused embryonic lethality, suggesting the irreplaceable role of GalNac-T14 in human development \[[@R31]\]. Germline mutations were also found in a recent study on the congenital disorders of glycosylation \[[@R32]\]. Finally, a genomic-screening of familial neuroblastoma also identified germline mutations which were responsible for the cancer \[[@R33]\]. Our recent studies also indicated a tight association between *GALNT14* genotype and chemotherapy or chemoembolization responses in advanced hepatocellular carcinoma patients. It is therefore not surprising to find that *GALNT14* genotype also associated with CCRT responses in advanced ESCC patients.

Recently, a single nucleotide polymorphism (rs9331888) in the 5′ untranslated region of the Clusterin gene was shown to be associated with the occurrence of ESCC based on a cross-sectional comparison between ESCC patients and healthy control subjects \[[@R34]\]. The "GG" genotype was shown to associate with higher risk of ESCC than the "CC+CG" genotypes \[[@R34]\]. In terms of treatments by definitive chemoradiotherapy, one other study showed that low Clusterin levels, detected by immunohistochemistry, were associated with complete response \[[@R17]\]. Despite these evidence, the roles of Clusterin in patients with distant metastasis remained unclear because such patients were excluded from previous studies. The higher expression levels of vascular endothelial growth factor (VEGF), measured by immunohistochemistry, was associated with higher rate of complete response of definitive CCRT in a multivariate analysis \[[@R21]\]. However, a meta-analysis of 19 studies on a wide spectrum of ESCC patients showed that VEGF positivity actually correlated with poor prognosis of ESCC patients \[[@R35]\]. Thus, conflicting evidence of VEGF in ESCC remained to be resolved.

In conclusion, a complete/partial response to CCRT in advanced ESCC patients is critical for them to achieve a longer survival. The *GALNT14* genotype "TT+TG" were associated with a higher chance of complete/partial response to CCRT, whereas the "GG" genotype was associated with an unfavorable treatment outcome. Other adjuvant treatment, such as chemotherapies or targeted therapies may be needed for patients with the "GG" genotype.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

This retrospective study was approved by the institutional review board of Chang Gung Memorial Hospital (ID:103-3422B), conducted under the provisions of the Declaration of Helsinki. A computer database in cancer register center, Chang Gung Memorial Hospital, Linkou medical center was searched for patients satisfying the following inclusion criteria: patients who had newly diagnosed clinical stage IV ESCC based on endoscopic biopsy and imaging study from January 2007 to May 2013; patients received CCRT with chemotherapy regimen of a combination of cisplatin plus 5-fluorouracil; patients who were followed regularly; and patients who died of ESCC. A total of 135 patients fulfilled the inclusion criteria. Among them, 27 patients did not have specimens available in the Tissue bank of Chang Gung Memorial Hospital, and were excluded from this study. As a result, 108 patients were analyzed in this study. All of them have given informed consent before depositing their samples to the Tissue Bank. The CCRT protocol has been published previously \[[@R8], [@R9]\]. Briefly, cisplatin was given by intravenous infusion, 75 mg/m^2^ per day over 3 hours on day 1, and 5-fluorouracil was given 1000 mg/m^2^ per day, by continuous infusion over 96 hours at days 1-4, repeated every 28 days, 2-4 cycles. Radiation was given between days 8 and 29 for 200 cGy per daily fraction, 5 days a week, to a total dose of 30 Gy. The treatment efficacy was evaluated by Computed Tomography (CT), taken before and 4-6 weeks after the treatment, according to the Response Evaluation Criteria in Solid Tumours (RECIST) definition \[[@R29]\].

The patients were given CCRT because they were diagnosed as stage IV ESCC patients under the definitions of the American Joint Committee on Cancer (AJCC) 6^th^ edition before 2010 and 7^th^ edition \[[@R36]\] after 2010. Since the definitions of the two editions was slightly different, we re-scored the metastatic status of all patients according to the definition of AJCC 7^th^ edition as: (1) regional lymph node (LN) metastasis, defined as any periesophageal LN from cervical nodes to celiac nodes; (2) distant LN metastasis, defined as LN metastasis beyond the regional LNs without organ metastasis; and (3) organ metastasis. Clinical parameters were collected and recorded, including age, gender, tumor locations and stages, histologic grade, Eastern Cooperative Oncology Group (ECOG) performance status \[[@R37]\], and tumor length (based on CT scans). Biochemistry and hemogram analysis included albumin, bilirubin, alanine transaminase (ALT), creatinine, leukocyte count, percentage of neutrophils, and hemoglobin.

GALNT14 genotyping {#s4_2}
------------------

G*e*notyping of *GALNT14* was performed using the previously-described technology \[[@R24], [@R25]\]. In short, nuclear DNA was extracted and purified from the non-tumor part of the formalin-fixed, paraffin-embedded esophageal biopsied specimens. The primers were as follows: forward, 5′-TCACGAGGCCAACATTCTAG-3′ and reverse, 5′-TTAGATTCTGCATGGCTCAC-3′. They were used for PCR and direct sequencing for a 172-bp intronic region of *GALNT14* covering rs9679162. The SNPs determined from both directions of sequencing were completely matched in all samples.

Statistical analysis {#s4_3}
--------------------

Genotype data were analyzed by Cochran-Armitage Trend test. Dichotomized data were presented as ratios (%) and compared by the Chi-square tests. Survival analysis was performed by analyzing time to events from the date of initial treatment to the occurrence of events or loss of follow-up, where the events included death and therapeutic response defined by the RECIST criteria \[[@R29]\]. The loss of follow up was treated as the censored data in the survival analysis. The univariate and multivariate Cox proportional hazards model was used for the survival analyses with respect to clinical and genotypic variables. Multivariable analysis was performed only on variables which showed significant associations in the univariate analysis. Following dichotomized stratification of patients by their genotypes, the Kaplan-Meier method was used to estimate the survival probability between groups, and the log-rank test was used to compare survival outcomes. P\<0.05 was considered a statistically significant difference. The SPSS version 17 software were used for the analysis (SPSS, Inc., Chicago, IL, USA).
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